NDA 019949 · Pfizer
Diflucan
Fluconazole · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Jan 29, 1990
Approved uses
3
Original approval plus efficacy supplements
Registered trials
259
66 Phase 3, 22 recruiting
FAERS reports
70,762
59,877 serious, 12,605 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 23, 1994 Supplement 12 · Efficacy · priority review
- Dec 30, 1993 Supplement 3 · Efficacy
- Jan 29, 1990 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
- DIFLUCAN · FLUCONAZOLE 150MG · TABLET, ORAL · Prescription · TE AB
- DIFLUCAN · FLUCONAZOLE 100MG · TABLET, ORAL · Prescription · TE AB
- DIFLUCAN · FLUCONAZOLE 200MG · TABLET, ORAL · Prescription · TE AB
- DIFLUCAN · FLUCONAZOLE 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluconazole" as an intervention, any sponsor and status, largest first.
- Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 YearsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT01712984 · 3,360 participants · Start Oct 2012 · Primary completion Jun 2013
Drug: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation; Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal and 1 more · For: Influenza
Sites: Hoover, Alabama; Huntsville, Alabama; Chandler, Arizona · 38 sites in all
University of MinnesotaAcademic, hospital or other
NCT01535469 · 3,049 participants · Start Jul 1, 2012 · Primary completion Jun 2015
Drug: Fluconazole · For: Cryptococcal Meningitis; Cryptococcus Neoformans; Cryptococcosis
Sites: Kampala, Uganda · 2 sites in all
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04498832 · 2,100 participants · Start Oct 21, 2020 · Primary completion Jan 14, 2021
Drug: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD); Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD) · For: Influenza Immunization; Healthy Volunteers
Sites: Fukuoka, Japan; Koganeishi, Japan; Kumamoto, Japan · 10 sites in all
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)Pivotal-lookingRecruiting
David BoulwareAcademic, hospital or other
NCT06666322 · 2,000 participants (planned) · Start May 28, 2025 · Primary completion Apr 21, 2032
Drug: Standard of care; Oteseconazole - antifungal therapy 1 and 3 more · For: Hiv; Cryptococcal Meningitis
Sites: Kampala, Uganda; Mbarara, Uganda
- Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral TherapyPivotal-lookingCompleted
Anna Griffiths, MRCGovernment (non-federal)
NCT01825031 · 1,805 participants · Start Jun 2013 · Primary completion Mar 2016
Drug: Raltegravir; Fluconazole and 3 more · For: Human Immunodeficiency Virus
Sites: Eldoret, Kenya; Kilifi, Kenya; Blantyre, Malawi · 8 sites in all
- Study of the Management of Vaginal Discharge in West African Using Single Dose TreatmentsPivotal-lookingCompleted
Université de SherbrookeAcademic, hospital or other
NCT00313131 · 1,524 participants · Start Jan 2004
Drug: tinidazole+fluconazole vs metronidazole+clotrimazole · For: Bacterial Vaginosis; Candidiasis; Vaginitis
Sites: Accra, Ghana; Kumasi, Ghana; Conakry, Guinea · 7 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,269
- off label use4,705
- pyrexia4,261
- nausea3,868
- diarrhoea3,655
- fatigue3,320
- pain3,210
- drug interaction3,089
- headache2,999
- pneumonia2,937
- febrile neutropenia2,741
- rash2,522
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,081 |
| 2005 | 1,191 |
| 2006 | 1,243 |
| 2007 | 1,184 |
| 2008 | 1,359 |
| 2009 | 1,567 |
| 2010 | 1,650 |
| 2011 | 2,504 |
| 2012 | 2,479 |
| 2013 | 2,100 |
| 2014 | 2,290 |
| 2015 | 3,173 |
| 2016 | 3,829 |
| 2017 | 3,887 |
| 2018 | 5,023 |
| 2019 | 5,586 |
| 2020 | 5,251 |
| 2021 | 4,995 |
| 2022 | 4,531 |
| 2023 | 4,172 |
| 2024 | 4,469 |
| 2025 | 4,315 |
| 2026 | 2,874 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Diflucan (Fluconazole)
2024 spending
$335K
Beneficiaries
206
348 claims
Per beneficiary
$1,627
$23.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $544,440 |
| 2021 | $539,499 |
| 2022 | $322,406 |
| 2023 | $229,457 |
| 2024 | $335,102 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Fluconazole pharmacokinetics in burn patients.
Boucher BA, King SR, Wandschneider HL, et al. · Antimicrob Agents Chemother 1998 · Clinical Trial, Randomized Controlled Trial
- Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial.
Mollazadeh-Narestan Z, Yavarikia P, Homayouni-Rad A, et al. · Probiotics Antimicrob Proteins 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ocular manifestations of candidemia.
Oude Lashof AM, Rothova A, Sobel JD, et al. · Clin Infect Dis 2011 · Multicenter Study, Randomized Controlled Trial
- Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.
Awotiwon AA, Johnson S, Rutherford GW, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Nystatin prophylaxis and treatment in severely immunodepressed patients.
Gøtzsche PC, Johansen HK · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.